US 10603326
Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime
granted A61KA61K31/437A61K31/568
Quick answer
US patent 10603326 (Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime) held by Umecrine Cognition AB expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Umecrine Cognition AB
- Grant date
- Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K31/437, A61K31/568, A61K31/569, A61K31/7016